ZTX® PREDICT

About BioReperia

BioReperia leverages its proprietary ZTX® platform, utilizing humanized zebrafish models, to accelerate and improve oncology drug discovery and clinical decision-making. The platform provides rapid, in-vivo data within five days, serving biopharma clients, academia, and healthcare professionals. The company recently underwent a leadership transition, appointing a new CEO with a strong biotech background to drive growth. BioReperia operates as a service and platform provider, generating early revenue through collaborations and research services.

Therapeutic Areas